Cargando…
Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USP...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662997/ https://www.ncbi.nlm.nih.gov/pubmed/23606432 http://dx.doi.org/10.1002/cmmi.1526 |
_version_ | 1782270915984228352 |
---|---|
author | Shi, Qiaoyun Pisani, Laura J Lee, Yauk K Messing, Solomon Ansari, Celina Bhaumik, Srabani Lowery, Lisa Lee, Brian D Meyer, Dan E Daldrup-Link, Heike E |
author_facet | Shi, Qiaoyun Pisani, Laura J Lee, Yauk K Messing, Solomon Ansari, Celina Bhaumik, Srabani Lowery, Lisa Lee, Brian D Meyer, Dan E Daldrup-Link, Heike E |
author_sort | Shi, Qiaoyun |
collection | PubMed |
description | Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) compound GEH121333; (2) assess whether GEH121333 can serve as a MR imaging biomarker for TAM; and (3) compare tumor MR enhancement profiles between GEH121333 and ferumoxytol. Blood half-lives of GEH121333 and ferumoxytol were measured by relaxometry (n = 4 each). Tolerance was assessed in healthy rats injected with high dose GEH121333, vehicle or saline (n = 4 each). Animals were monitored for 7 days regarding body weight, complete blood counts and serum chemistry, followed by histological evaluation of visceral organs. MR imaging was performed on mice harboring MMTV-PyMT-derived breast adenocarcinomas using a 7 T scanner before and up to 72 h post-injection (p.i.) of GEH121333 (n = 10) or ferumoxytol (n = 9). Tumor R(1), R(2)* relaxation rates were compared between different experimental groups and time points, using a linear mixed effects model with a random effect for each animal. MR data were correlated with histopathology. GEH121333 showed a longer circulation half-life than ferumoxytol. Intravenous GEH121333 did not produce significant adverse effects in rats. All tumors demonstrated significant enhancement on T(1), T(2) and T(2)*-weighted images at 1, 24, 48 and 72 h p.i. GEH121333 generated stronger tumor T(2)* enhancement than ferumoxytol. Histological analysis verified intracellular compartmentalization of GEH121333 by TAM at 24, 48 and 72 h p.i. MR imaging with GEH121333 nanoparticles represents a novel biomarker for TAM assessment. This new USPIO MR contrast agent provides a longer blood half-life and better TAM enhancement compared with the iron supplement ferumoxytol. Copyright © 2013 John Wiley & Sons, Ltd. Supporting information may be found in the online version of this paper |
format | Online Article Text |
id | pubmed-3662997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36629972013-05-24 Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses Shi, Qiaoyun Pisani, Laura J Lee, Yauk K Messing, Solomon Ansari, Celina Bhaumik, Srabani Lowery, Lisa Lee, Brian D Meyer, Dan E Daldrup-Link, Heike E Contrast Media Mol Imaging Full Papers Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) compound GEH121333; (2) assess whether GEH121333 can serve as a MR imaging biomarker for TAM; and (3) compare tumor MR enhancement profiles between GEH121333 and ferumoxytol. Blood half-lives of GEH121333 and ferumoxytol were measured by relaxometry (n = 4 each). Tolerance was assessed in healthy rats injected with high dose GEH121333, vehicle or saline (n = 4 each). Animals were monitored for 7 days regarding body weight, complete blood counts and serum chemistry, followed by histological evaluation of visceral organs. MR imaging was performed on mice harboring MMTV-PyMT-derived breast adenocarcinomas using a 7 T scanner before and up to 72 h post-injection (p.i.) of GEH121333 (n = 10) or ferumoxytol (n = 9). Tumor R(1), R(2)* relaxation rates were compared between different experimental groups and time points, using a linear mixed effects model with a random effect for each animal. MR data were correlated with histopathology. GEH121333 showed a longer circulation half-life than ferumoxytol. Intravenous GEH121333 did not produce significant adverse effects in rats. All tumors demonstrated significant enhancement on T(1), T(2) and T(2)*-weighted images at 1, 24, 48 and 72 h p.i. GEH121333 generated stronger tumor T(2)* enhancement than ferumoxytol. Histological analysis verified intracellular compartmentalization of GEH121333 by TAM at 24, 48 and 72 h p.i. MR imaging with GEH121333 nanoparticles represents a novel biomarker for TAM assessment. This new USPIO MR contrast agent provides a longer blood half-life and better TAM enhancement compared with the iron supplement ferumoxytol. Copyright © 2013 John Wiley & Sons, Ltd. Supporting information may be found in the online version of this paper Blackwell Publishing Ltd 2013-05 2013-03-13 /pmc/articles/PMC3662997/ /pubmed/23606432 http://dx.doi.org/10.1002/cmmi.1526 Text en Copyright © 2013 John Wiley & Sons, Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Full Papers Shi, Qiaoyun Pisani, Laura J Lee, Yauk K Messing, Solomon Ansari, Celina Bhaumik, Srabani Lowery, Lisa Lee, Brian D Meyer, Dan E Daldrup-Link, Heike E Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title | Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title_full | Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title_fullStr | Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title_full_unstemmed | Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title_short | Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses |
title_sort | evaluation of the novel uspio geh121333 for mr imaging of cancer immune responses |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662997/ https://www.ncbi.nlm.nih.gov/pubmed/23606432 http://dx.doi.org/10.1002/cmmi.1526 |
work_keys_str_mv | AT shiqiaoyun evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT pisanilauraj evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT leeyaukk evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT messingsolomon evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT ansaricelina evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT bhaumiksrabani evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT lowerylisa evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT leebriand evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT meyerdane evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses AT daldruplinkheikee evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses |